European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Map My Mole, by Community Dermatology Limited, is a service that offers remote assessments of moles and skin lesions by consultant dermatologists.
Their missions in to bring skin checks to where the patient is, whether at home or in one…
Working in collaboration with partners across health and care, its multi-disciplinary team carries out health technology assessments of health or care technologies that are not a medicine and publishes national guidance on their use in Wales.
Read more here.
Attendees
Sponsors and
Exhibitors
Webinars
Contact us